

From: Hollenshead, Bernie R SCC
Sent: Thursday, September 05, 2002 12:34 PM
To: Clegg, Patsy M SCC-CHSE-PC
Subject: RE: Benzene Producers in the US

There are some 15 or more producers of Bz in the US. However the large ones are Exxon, BP, Dow, Chevron-Phillips, ConocoPhillips, Citgo, and Flinthills(Koch). In order: Mark Myers,281/870-6790; Hunter Henderlite, 630/961-6982; Robbie Dahlgren,713/978-3349; Mark Graham,832/813-4239; none at Conoco; Phil Reedy,918/495-5232; Greg Richards,316/828-8317 . All are commercial types but they shd know the HSE focal point for Bz.

Bernie Hollenshead
Sales Director - Aromatics
Shell Chemical LP
One Shell Plaza, P.O. Box 2463, Houston, TX 77252-2463

Tel: +1 713 241 3492 **Fax:** 8540
Email: brhollenshead@shellus.com
Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: Clegg, Patsy M SCC-CHSE-PC
Sent: Thursday, August 29, 2002 2:40 PM
To: Hollenshead, Bernie R SCC
Subject: Benzene Producers in the US

Bernie,

Working on recruiting new sponsors for the benzene study in Shanghai. Would you please provide me with a list of benzene producers in the US. If you have a name and telephone number for a potential contact within the company, that would be great. Also, producers outside the US are being sought.

Patsy Clegg
Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 **Fax:** 3325
Email: pmclegg@shellus.com
Internet: <http://www.shell.com/chemicals>

	A	B	C	D	E
1			Approved	Approved	Approved
2	Item		21-Jun-07	7-Aug-08	23-Oct-08
3	AHSciences Case-Control Study		\$ 3,819,119	\$ 3,819,119	\$ 3,997,919
4	DP & ME Studies (UCHSC)		\$ 20,045,469	\$ 20,500,602	\$ 20,500,602
5	Irons(T & E)		\$ 1,413,428	\$ 1,413,428	\$ 1,413,428
6	Fudan University		\$ 444,829	\$ 444,829	\$ 444,829
7	Cinpathogen		\$ 4,847,740	\$ 4,847,740	\$ 4,847,740
8		Total Research Costs	\$ 30,570,585	31,025,718	31,204,518
9	Scientific Review Panel		\$ 446,950	\$ 446,950	\$ 487,950
10	Ethics Review Panel		\$ 166,192	\$ 166,192	\$ 232,858
11	External Pathology & Cytogenetics (Cost in UC cost)		\$ -	\$ -	\$ -
12	Exposure Assessment		\$ 109,000	\$ 109,000	\$ 109,000
13		Total Panel Costs	\$ 722,142	722,142	829,808
14	API Seed Monies		\$ -	\$ -	\$ -
15	Outside Counsel		\$ 245,000	\$ 245,000	\$ 245,000
16	Communications		\$ 500,000	\$ 500,000	\$ 500,000
17	QA/QC Activities		\$ 200,000	\$ 300,000	\$ 300,000
18	UCHSC Interest		\$ -	\$ -	\$ -
19	Committed funds		\$ 156,391	\$ 216,391	\$ 216,391
20	Contingency		\$ 1,227,395	\$ 612,262	\$ 225,796
21		Miscellaneous Costs	\$ 2,328,786	1,873,653	1,487,187
22		Subtotal	\$ 33,621,513	33,621,513	33,521,513
23		API Admin.	\$ 1,609,629	\$ 1,609,629	\$ 1,709,629
24	GRAND TOTAL		\$ 35,231,142	\$ 35,231,142	\$ 35,231,142
25	Cummulative Interest Earned		\$ 343,198	\$ 505,540	\$ 538,242

Benzene Health Research Consortium
Executive Summary
Financial Report
(Through September 08)

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
1																
2																
3			Actuals				ACTUALS							PROJECTED		
4			Inception													
5			Thru	Actuals	Actuals	Actuals	ACTUALS	ACTUALS	Balance in	Actuals +				PROJECTED	PROJECTED	
6			December	Jan - Dec	Jan - Dec	Jan - Dec	Jan - Sept	Program	contract	balance				for 2008	2009	
7	Cost Centers	Project #	2004	2005	2006	2007	2008	to 9/30/08		Thru Sept 08						
8																
9	Income		\$ 16,765,693	\$ 5,206,657	\$ 6,938,163	\$ 4,350,896	\$ 2,486,785	\$ 35,748,194		\$ 35,748,194				\$ 25,000	\$ -	
10																
11	Cost Centers															
12	UCHSC*	X8105	10,137,850	3,624,030	4,000,000	1,570,889	1,167,733	20,500,502	-	20,500,502				-	10,000	
13	Irons-Field Expense*	X8106	788,486	262,000	262,000	17,526	-	1,330,012	-	1,330,012				-	-	
14	Applied Health Sciences	X8107	1,391,014	548,720	558,214	632,124	479,142	3,609,215	155,014	3,764,229				-	10,000	
15	Fudan University	X8108	124,090	4,007	76,377	-	84,695	289,169	60,926	350,095				-	40,000	
16	Scientific & Ethics Panels	X8109	181,713	76,176	95,418	43,869	81,245	478,423	94,600	573,023				-	169,000	
17	Communications	X8103	294,161	-	-	-	4,309	298,470	-	298,470				-	50,000	
18	Outside Legal Counsel	X8104	64,529	33,706	39,154	53,546	7,642	198,578	28,437	227,015					10,000	
19	QA/QC Support	X8110	-	-	1,202	64,976	11,635	77,814	235,720	313,534					10,000	
20	API Administrative	X8100	856,208	130,475	161,327	148,213	142,810	1,439,034	-	1,439,034				48,000	100,000	
21	Exposure Assessment	x8111	-	-	12,324	27,197	52,394	91,915	8,178	100,093				-	-	
22	Cinpathogen	x8112			-	3,310,627	967,389	4,278,016	569,722	4,847,738				-	470,000	
23	Committed Contingency		104,473	51,918	-	2,495	1,096	159,983	-	159,983				60,000	(34,000)	
24	Uncommitted Contingency						-	-		-				-	-	
25	Total Expenses		\$ 13,942,525	\$ 4,731,033	\$ 5,206,017	\$ 5,871,463	\$ 3,000,091	\$ 32,751,129	\$ 1,152,597	\$ 33,903,726				\$ 108,000	\$ 835,000	
26																
27	Yearly Activity		\$ 2,823,169	\$ 475,624	\$ 1,732,146	\$ (1,520,567)	\$ (513,306)	\$ 2,997,065		\$ 1,844,468						
28								0.00								
29	Fund Balance		\$ 2,823,169	\$ 3,298,793	\$ 5,030,939	\$ 3,510,371	\$ 2,997,065			\$ 1,844,468						

Benzene Health Research Consortium
Executive Summary
Financial Report
(Through September 08)

	Q	R	S	T
1				
2				
3			BUDGET	
4				
5		PROJECTED		
6		End of	Program	
7		Project	Budget	
8		Income		
9		35,773,194	\$ 35,231,142	
10				
11		Expenses		
12		20,510,502	20,500,602	
13		1,330,012	1,413,428	
14		3,774,229	3,997,919	
15		390,095	444,829	
16		742,023	720,808	
17		348,470	500,000	
18		237,015	245,000	
19		323,534	300,000	
20		1,587,034	1,709,629	
21		100,093	109,000	
22		5,317,738	4,847,740	
23		185,983	\$ 216,391	
24		-	225,796	
25		\$ 34,846,726	\$ 35,231,142	
26				
27				
28				
29		\$ 926,468		

**SHS Cumulative Case Accrual Figures, WHO classification (approximate 6-month increments)
Revision 3 – combines data from progress reports and RDI ppt presentations, 2005-2006**

3 years of accrual = 6 x 6 mos.	July 03 – Dec 04 (3 x 6 months)				Jan 05 – July 05 (~1 x 6 months)				Aug 05 – May 06 (~2 x 6 months)			
	Cases	Cases/ 6 mos.	Cum. cases	Cum Cases/ 6 mos.	Cases	Cases/ 6 mos.	Cum. cases	Cum Cases/ 6 mos.	Cases	Cases/ 6 mos.	Cum. cases	Cum Cases/ 6 mos.
AML	269	90	269	90	56	56	325	81	194 ^a	97	519 ^b	87
Lymphoid	261	87	261	87	55	55	316	79	204 ^a	102	520 ^c	87
MDS	192	64	192	64	39	39	231	58	148	74	379	63
AA	61	20	61	20	4	4	65	16	67	34	132 ^d	22
BP	25	8 ^d	25	8 ^d	2	2	27	7	5	3	32	5
Estimated AML accrual & projection	Accrue 500 WHO AML = 6 x 6 mos (3 yr from July 03 = July 06)				Accrue 500 WHO AML = 6.5 x 6 mos (3 yr 3 mo from July 03 = Oct 06)				Accrue 500 WHO AML = 6 x 6 mos (3 yr from July 03 = July 06; 500 cases actually accrued by May 06)			
Estimated lympho accrual & projection	Accrue 500 WHO lympho = 6 x 6 mos (3 yr from July 03 = July 06)				Accrue 500 WHO lympho = 6 x 6 mos (3 yr 3 mo from July 03 = Oct 06)				Accrue 500 WHO lympho = 6 x 6 mos (3 yr from July 03 = July 06)			

^a Calculated by subtraction of previously reported cases (Jan 05 – July 05) from cumulative cases reported at Houston meeting or in July 2006 DP_ME_EA Progress Report.

^b RD Irons' slide #2, Houston, Aug 2006

^c Footnote [°] to Table 1 of DP_ME_EA Progress Report, July 2006

^d Arithmetic errors in first and second versions of this table corrected.